Literature DB >> 25496114

Cognitive function and endogenous cytokine levels in children with chronic hepatitis C.

N H Abu Faddan1, G A Shehata2, H A Abd Elhafeez3, A O Mohamed4, H S Hassan5, F Abd El Sameea5.   

Abstract

Little is known about how hepatitis C (HCV) infection affects cognitive function in children. The aim of the study was to assess the impact of HCV infection on cognitive function of children with normal liver functions and their relationships to endogenous IFN-α, IL-6 and TNF-α. IFN-α, IL-6 and TNF-α were measured and the Arabic version of the Stanford-Binet test used to assess cognitive functions in 35 children with HCV infection and 23 controls. Serum levels of IL-6 and IFN-α were significantly higher in patients compared to controls. There was a significant effect on vocabulary, comprehension, and abstract visual reasoning, quantitative reasoning and bead memory tests, as well as total short-term memory and intelligence quotient in patients compared to controls. There was a significant positive correlation between IFN-α and IL-6. Also there were significant negative correlations between IFN-α and Abstract visual reasoning test, Quantitative reasoning test, Bead memory test, Total short-term memory and Intelligence quotient; and between IL-6 and Abstract visual reasoning test, Quantitative reasoning test and Intelligence quotient. There was no significant correlation between TNF-α and any of the cognitive functions. Cytokine levels were not related to demographic characteristics of the patients or viral load (PCR). Children with chronic hepatitis C infection in its early stages showed signs of cognitive impairment, with the memory tasks being mostly affected. There was a significant correlation between endogenous cytokines and cognitive impairment in these children. Further studies are needed to define the effect of successful antiviral treatment.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  children; cognitive function; cytokines; hepatitis C

Mesh:

Substances:

Year:  2014        PMID: 25496114     DOI: 10.1111/jvh.12373

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  Association between high levels of inflammatory markers and cognitive outcomes at 4 years of age: The Rhea mother-child cohort study, Crete, Greece.

Authors:  Andriani Kyriklaki; Katerina Margetaki; Mariza Kampouri; Katerina Koutra; Panos Bitsios; Georgia Chalkiadaki; Eirini Dermitzaki; Maria Venihaki; Katerina Sarri; Despoina Anousaki; Manolis Kogevinas; Leda Chatzi
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

2.  Event-related evoked potential versus clinical tests in assessment of subclinical cognitive impairment in chronic hepatitis C virus.

Authors:  Hanaa Khalaf Fath-Elbab; Elham Ahmed; Dina Fathy Mansour; Wail Talaat Soliman
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-11-20

3.  Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.

Authors:  Philip Rosenthal; Kathleen B Schwarz; Regino P Gonzalez-Peralta; Chuan-Hao Lin; Deidre A Kelly; Scott Nightingale; William F Balistreri; Sanjay Bansal; Maureen M Jonas; Benedetta Massetto; Diana M Brainard; Chia-Hsiang Hsueh; Jiang Shao; Bandita Parhy; Suzanne Davison; Cornelia Feiterna-Sperling; Lynette A Gillis; Giuseppe Indolfi; Etienne M Sokal; Karen F Murray; Stefan Wirth
Journal:  Hepatology       Date:  2019-08-13       Impact factor: 17.425

Review 4.  Cascade of care for children and adolescents with chronic hepatitis C.

Authors:  Michael Evan Rogers; William F Balistreri
Journal:  World J Gastroenterol       Date:  2021-03-28       Impact factor: 5.742

5.  Adolescents with chronic hepatitis C might be good candidates for direct-acting antiviral therapy.

Authors:  Ken Sato; Yuichi Yamazaki; Yuki Kanayama; Daisuke Uehara; Hiroki Tojima; Takayoshi Suga; Satoru Kakizaki; Naondo Sohara; Norio Horiguchi; Toshio Uraoka
Journal:  Clin Case Rep       Date:  2022-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.